Xeris Biopharma Files 8-K on Executive Changes
Ticker: XERS · Form: 8-K · Filed: Mar 28, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, governance, filing
Related Tickers: XERS
TL;DR
Xeris Biopharma 8-K: Exec changes, director elections, and comp arrangements filed 3/28.
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on March 28, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in executive officers and directors can signal internal shifts or strategic realignments that may affect the company's future performance.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- March 28, 2025 (date) — Date of earliest event reported
FAQ
What specific officer positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but the specific positions are not detailed in the provided text.
Were there any new directors elected to the Xeris Biopharma Holdings, Inc. board?
Yes, the filing explicitly lists 'Election of Directors' as an item being reported.
Does this filing detail any new compensatory arrangements for officers?
Yes, 'Compensatory Arrangements of Certain Officers' is listed as an item information for this 8-K filing.
What is the primary purpose of an 8-K filing like this one?
An 8-K filing is used to report significant events that shareholders should be aware of, such as changes in executive leadership or material financial information.
What is the business address of Xeris Biopharma Holdings, Inc. as listed in the filing?
The business address is 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Xeris Biopharma Holdings, Inc. (XERS).